New analysis indicates that omega-3 fatty acid supplements may provide slight cognitive benefits for children and adolescents with ADHD, highlighting their potential role as an adjunct to standard treatments amidst cautious optimism.
Omega-3 supplements may give children and adolescents with attention deficit hyperactivity disorder a modest boost, according to a new analysis that adds to a growing but still cautious body of evidence. Researchers at Duke Kunshan University in China reviewed 16 randomised controlled trials, bringing together results from multiple studies to assess whether polyunsaturated fatty acid supplements, particularly omega-3s, improve ADHD symptoms.
The analysis suggests that the clearest gains were seen on performance-based cognitive tests rather than on behaviour ratings completed by parents or teachers. In practical terms, that means children in some studies performed a little better on tasks measuring attention or related thinking skills, but the improvements were less obvious in day-to-day reports of hyperactivity, impulsivity or inattentiveness. The researchers did not present omega-3 supplements as a substitute for established ADHD treatments, but they did find a small overall benefit. Earlier research points in a similar direction: a meta-analysis of 10 trials involving 699 children found a small but significant improvement, with higher doses of eicosapentaenoic acid, or EPA, appearing more effective.
That earlier finding echoed an even smaller randomised, double-blind, placebo-controlled study that reported improvements in inattention and overall ADHD symptoms after omega-3 supplementation. Taken together, the studies do not amount to a clear answer that supplements will work for every child, but they do suggest there may be a role for them as an added measure rather than a replacement for standard care. The broader scientific picture remains mixed, with benefits tending to be modest rather than dramatic.
The context matters because ADHD is common in the United States. Data from the National Survey of Children’s Health in 2024 indicate that about seven million children aged three to 17 have a current diagnosis. For parents and caregivers, the new findings are best understood as tentative support for omega-3s as one possible piece of a wider treatment plan, not a stand-alone solution. Any decision to use supplements should still be weighed alongside established medical advice, especially since the strongest effects in the latest analysis were on test performance rather than on observable behaviour in everyday life.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
